Hakan Edstrom, president and CEO of MannKind, discussed in an interview further applications of the company’s signature drug-delivery technology, Technosphere.

The technology could potentially be used with drugs that are toxic to the liver, because Mannkind’s system bypasses the organ; drugs used for pain, pulmonary-related diseases and central nervous system diseases; and for smoking cessation, Ekstrom said.